Inactive

The present contract represents the competitive renewal of an existing NIDA contract. It provides support for evaluation of potential pharmacotherapies for drug use disorders using rodents. It also pr... The present contract represents the competitive renewal of an existing NIDA contract. It provides support for evaluation of potential pharmacotherapies for drug use disorders using rodents. It also provides support for abuse liability testing of new street drugs, medications, or potential medications in rodents. The primary emphasis is on testing conducted for NIDA’s Addiction Treatment Discovery Program (ATDP). To a lesser extent, the contract will generate abuse liability data for use in decisions pertaining to scheduling of drugs under domestic laws (Controlled Substances Act) and international treaties (Single Convention and Psychotropic Convention). Organizations must have in-house capability to perform in vivo rodent and primate pharmacology studies on potential pharmacotherapies for substance use disorders and on new drugs of abuse. This contract will be utilized by the Addiction Treatment Discovery Program (ATDP) within NIDA's Division of Therapeutics and Medical Consequences. Data gathered on potential pharmacotherapies will be used by the ATDP and NIDA's Medications Development Program. The data generated with new drugs of abuse will be provided to the DEA and FDA by NIDA. Testing shall include but shall not be limited to assessment of the in vivo receptor activity of novel opioid compounds, evaluation of compounds for their ability to produce or prevent physical dependence in rodents and/or primates, evaluation of compounds for their ability to ameliorate withdrawal symptoms in drug dependent animals, evaluation of compounds in operant models of behavior, including responding for food reinforcement and intracranial self-stimulation, and evaluation of compounds in other animal models relevant to drug abuse and addiction. Contractors will be blinded to the identity of proprietary test compounds, and all compounds will be evaluated using protocols and experimental parameters as specified by the NIDA Contracting Officer's Representative. Standardized, detailed reports with graphs will be prepared and submitted promptly to the ATDP for each compound tested. It is expected that 10-20 compounds will be evaluated per year in operant behavioral models. The number of compound evaluations in other models will vary significantly from year to year. The successful offeror must indicate possession of current DEA registration for Schedule II-V substances prior to award and apply for appropriate Schedule I registration. Offerors shall meet the following Mandatory Criteria: 1. DEA RESEARCH REGISTRATION: This project involves the use of scheduled drugs under the Controlled Substances Act of 1970. Due to the nature of compounds which will be evaluated, the Offeror shall indicate possession of a current DEA registration for Schedule II-V substances prior to award, and must obtain DEA registration for Schedule I controlled substances after contract award. 2. ANIMAL WELFARE: This research involves the use of animals. The Offeror must demonstrate its understanding and compliance with the NIH Guide for Care and Use of Laboratory Animals. The Offeror shall submit evidence that its proposal was reviewed and approved by the institution and that the institution has Animal Welfare Assurances in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals prior to award. NIDA anticipates that one (1) cost-reimbursement, level of effort type contract will be awarded with a base period of 12 months with four 12-month options. Furthermore there will be additional option quantities for each period for additional labor hours and costs (supplies, animal purchases, animal per diem, equipment, etc.) related to completing the statement of work. The options will be exercised in accordance with FAR Clauses 52.217-7 Option for Increased Quantity-Separately Priced Line Item and 52.217-9 Option to Extend the Term of the Contract. All submissions must be received no later than Monday, November 22, 2021, 10:00 A.M. Eastern Time. Please see attached Request for Proposal for all relevant details and submission instructions. Please see attached Amendment 01 to the Request for Proposal which publicly answers questions submitted by interested vendors. Submission due date remains unchanged.

Inactive

Description: The National Institute on Drug Abuse (NIDA) intends to solicit proposals from offerors having the capability to perform the following: organizations must have in-house capability to perfo... Description: The National Institute on Drug Abuse (NIDA) intends to solicit proposals from offerors having the capability to perform the following: organizations must have in-house capability to perform in vivo rodent and primate pharmacology studies on potential pharmacotherapies for substance use disorders and on new drugs of abuse. This contract will be utilized by the Addiction Treatment Discovery Program (ATDP) within NIDA's Division of Therapeutics and Medical Consequences (DTMC). The present contract represents the competitive renewal of an existing NIDA contract. It provides support for evaluation of potential pharmacotherapies for drug use disorders using rodents. It also provides support for abuse liability testing of new street drugs, medications, or potential medications in rodents. The primary emphasis is on testing conducted for NIDA’s Addiction Treatment Discovery Program (ATDP). To a lesser extent, the contract will generate abuse liability data for use in decisions pertaining to scheduling of drugs under domestic laws (Controlled Substances Act) and international treaties (Single Convention and Psychotropic Convention). Organizations must have in-house capability to perform in vivo rodent and primate pharmacology studies on potential pharmacotherapies for substance use disorders and on new drugs of abuse. This contract will be utilized by the Addiction Treatment Discovery Program (ATDP) within NIDA's Division of Therapeutics and Medical Consequences. Data gathered on potential pharmacotherapies will be used by the ATDP and NIDA's Medications Development Program. The data generated with new drugs of abuse will be provided to the DEA and FDA by NIDA. Testing shall include but shall not be limited to assessment of the in vivo receptor activity of novel opioid compounds, evaluation of compounds for their ability to produce or prevent physical dependence in rodents and/or primates, evaluation of compounds for their ability to ameliorate withdrawal symptoms in drug dependent animals, evaluation of compounds in operant models of behavior, including responding for food reinforcement and intracranial self-stimulation, and evaluation of compounds in other animal models relevant to drug abuse and addiction. Contractors will be blinded to the identity of proprietary test compounds, and all compounds will be evaluated using protocols and experimental parameters as specified by the NIDA Contracting Officer's Representative. Standardized, detailed reports with graphs will be prepared and submitted promptly to the ATDP for each compound tested. It is expected that 10-20 compounds will be evaluated per year in operant behavioral models. The number of compound evaluations in other models will vary significantly from year to year. The successful offeror must indicate possession of current DEA registration for Schedule II-V substances prior to award and apply for appropriate Schedule I registration. Offerors shall meet the following Mandatory Criteria: DEA RESEARCH REGISTRATION: This project involves the use of scheduled drugs under the Controlled Substances Act of 1970. Due to the nature of compounds which will be evaluated, the Offeror shall indicate possession of a current DEA registration for Schedule II-V substances prior to award, and must obtain DEA registration for Schedule I controlled substances after contract award. ANIMAL WELFARE: This research involves the use of animals. The Offeror must demonstrate its understanding and compliance with the NIH Guide for Care and Use of Laboratory Animals. The Offeror shall submit evidence that its proposal was reviewed and approved by the institution and that the institution has Animal Welfare Assurances in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals prior to award. NIDA anticipates that one (1) cost-reimbursement, level of effort type contract will be awarded with a base period of 12 months with four 12-month options. Furthermore there will be additional option quantities for each period for additional labor hours and costs (supplies, animal purchases, animal per diem, equipment, etc.) related to completing the statement of work. The options will be exercised in accordance with FAR Clauses 52.217-7 Option for Increased Quantity-Separately Priced Line Item and 52.217-9 Option to Extend the Term of the Contract. RFQ No. 75N95021R00048 will be available electronically on or about September 06, 2021. You can access the RFP through the Beta.SAM. All information required for the submission of a quote will be contained in or accessible through the RFQ package. Responses to the RFQ will be due on or around October 21, 2021. NIDA will consider quotes submitted by any responsible offeror. This advertisement does not commit the Government to award a contract. Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the Contracting Officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice. This advertisement does not commit the Government to award a contract.

Inactive

This is a Small Business Sources Sought (SBSS) notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) t... This is a Small Business Sources Sought (SBSS) notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources? (2) whether they are small businesses? HUBZone small businesses? service disabled, veteran-owned small businesses? 8(a) small businesses? veteran-owned small businesses? woman-owned small businesses? or small disadvantaged businesses? and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability and type of qualified Small Business companies technically capable of meeting this potential government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. The notice is strictly for research and information purposes only. The information requested will assist the Government in determining the appropriate acquisition method including small business socioeconomic set aside possibilities and to determine the availability of qualified Small Business companies technically capable of meeting the Government's potential requirement. All Small Business companies with the capability and availability to perform the requirement under the applicable NAICS code are invited to submit a response to this notice. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 541715 -- Physical science research and development laboratories or services (except biotechnology and nanotechnology research and development) Manufacturing with a Size Standard of 1,000 employees. DESCRIPTION OF REQUIREMENT Background The present contract represents the competitive renewal of an existing NIDA contract. It provides support for evaluation of potential pharmacotherapies for drug use disorders using rodents. It also provides support for abuse liability testing of new street drugs, medications, or potential medications in rodents. The primary emphasis is on testing conducted for NIDA’s Addiction Treatment Discovery Program (ATDP). To a lesser extent, the contract will generate abuse liability data for use in decisions pertaining to scheduling of drugs under domestic laws (Controlled Substances Act) and international treaties (Single Convention and Psychotropic Convention). Organizations must have in-house capability to perform in vivo rodent and primate pharmacology studies on potential pharmacotherapies for substance use disorders and on new drugs of abuse. This contract will be utilized by the Addiction Treatment Discovery Program (ATDP) within NIDA's Division of Therapeutics and Medical Consequences. Data gathered on potential pharmacotherapies will be used by the ATDP and NIDA's Medications Development Program. The data generated with new drugs of abuse will be provided to the DEA and FDA by NIDA. Testing shall include but shall not be limited to assessment of the in vivo receptor activity of novel opioid compounds, evaluation of compounds for their ability to produce or prevent physical dependence in rodents and/or primates, evaluation of compounds for their ability to ameliorate withdrawal symptoms in drug dependent animals, evaluation of compounds in operant models of behavior, including responding for food reinforcement and intracranial self-stimulation, and evaluation of compounds in other animal models relevant to drug abuse and addiction. Contractors will be blinded to the identity of proprietary test compounds, and all compounds will be evaluated using protocols and experimental parameters as specified by the NIDA Contracting Officer's Representative. Standardized, detailed reports with graphs will be prepared and submitted promptly to the ATDP for each compound tested. It is expected that 10-20 compounds will be evaluated per year in operant behavioral models. The number of compound evaluations in other models will vary significantly from year to year. The successful offeror must indicate possession of current DEA registration for Schedule II-V substances prior to award and apply for appropriate Schedule I registration. The established NAICS code is 541715. Information sent should be relevant and specific in the technical area under consideration, on each of the following qualifications: 1) Experience: An outline of previous similar projects, specifically the techniques employed in the areas described above; and 2) Personnel: Name, professional qualifications and specific experience in the work requested and knowledge of, and experience in, the field of research. Any other specific and relevant information about this particular area of procurement that would improve our consideration and evaluation of the information presented is desirable. Interested organizations must demonstrate and document, in any capability statements submitted, extensive experience with and the ability to perform the above tasks. Organizations should demonstrate capability to administer and coordinate interrelated tasks in an effective and timely manner. Documentation may include, but not be limited to, contracts both Government and commercial the organization performed, references, i.e., names, titles, telephone numbers and any other information serving to document the organizations capability, e.g., awards, commendations, etc. CAPABILITY STATEMENT Interested parties are expected to review this notice to familiarize itself with the requirements of this product or service. Failure to do so will be at your firm's own risk. The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc.) pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11point or 12point font, 8-1/2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. The information submitted must be in an outline format that addresses each of the elements of the product requirement. A cover page and an executive summary may be included but is not required. The response must include the respondents' technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and email addresses. Respondents must reference announcement number 75N95021R00048 on all correspondence related to this Small Business Sources Sought notice. The response must be submitted electronically to alexander.beraud@nih.gov and tracy.cain@nih.gov and be received prior to the closing date specified in this announcement. The response must be received on or before July 22, 2020, 11:00 am, Eastern Time. CONCLUDING STATEMENTS Disclaimer and Important Notes. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in beta.SAM. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any nonproprietary technical information in any resultant solicitation(s).